Global Liquid Biopsy Products Market By Application (Circulating tumor cells (CTC) in the blood, Cell free DNA from tumor or fetus cells (in the blood), Molecular Diagnostics, Early Stage Cancer – Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Ovarian Cancer, Others, Non-invasive prenatal tests (NIPT), Others); By Size (5 ml, 50 ml, 100 ml, 250 ml, Above 250 ml); By Offering (Instruments – Blood Collection Tube (BCT) for cfDNA and CTCs, Target Selector Kits, Cell Free DNA Extraction Kit, Cell Free Nucleic Acid Extraction Kit, Mutation Quantification Control Plasma, Genomic profiling diagnostic kit, Target Selector NGS Panels, PCR Purification Kit, Blood Nucleic Acid Extraction, Viral Nucleic Acid Extraction, Others, Reagents, Liquid Biopsy Assays, Tools, Services – Custom Services, Support Services, Others); By End User (Hospitals/ Clinics, Pathology Laboratories, Physician Laboratories, Academic and Research Centers, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1372 | Category : Healthcare | Published Date : December, 2022 | Pages : 402 | Format :PDF

Industry Trends

Global liquid biopsy products market is expected to reach US$ 18.5 Bn by 2030, growing at an estimated CAGR of 20% over the forecast period. Fluid biopsy or fluid phase biopsy, more commonly known as liquid biopsy basically happens to be sampling and analysis of biological tissue that is non-solid, mainly blood. Similar to conventional biopsy, this type of test/ method is basically used as a diagnostic and monitoring tool for dreadful ailments like cancer. This technique is non-invasive and this is what gives it an edge when it comes to diagnose cancer. Liquid biopsies are more likely to be used to grant validation to the efficacy of any type of cancer treatment drug by testing various samples within the period of few weeks. Owing to multiple factors, the global liquid biopsy products market is exponentially growing.

The COVID-19 pandemic positively impacted the growth of the global liquid biopsy products market. Higher prevalence of dreadful infection in people with co-morbidities or any life-threatening disease like cancer helped this market grow.

By Application

On the basis of application, the global liquid biopsy products market has been bifurcated into circulating tumor cells (CTC) in the blood, cell free DNA from tumor or fetus cells (in the blood), molecular diagnostics, early-stage cancer, non-invasive prenatal tests (NIPT) and others. The early-stage cancer segment has been further categorised into lung cancer, breast cancer, colorectal cancer, gastric cancer, prostate cancer, liver cancer, bladder cancer, ovarian cancer and others. Rising prevalence of cancer in people across the globe, especially those aging below thirty is the reason why this segment accounts for majority of revenue generated by this market.

Global Liquid Biopsy Products Market Revenue & Forecast, (US$ Million), 2022 – 2030

By Size

The size segment of the global liquid biopsy products market has been bifurcated into 5 ml, 50 ml, 100 ml, 250 ml, and above 250 ml. The 250 ml segment mints major chunk of money for this market as this sample size tests blood and tissue. This helps determine efficacy of the treatment in the quickest way and hence preferred the most by the medical experts across the globe.

By Offering

On the basis of offering, the global liquid biopsy products market has been divided into instruments, reagents, liquid biopsy assays, tools, services and others. The instruments segment is further segmented into blood collection tube (BCT) for cfDNA and CTCs, target selector kits, cell free DNA extraction kit, cell free nucleic acid extraction kit, mutation quantification control plasma, genomic profiling diagnostic kit, target selector NGS panels, PCR purification kit, blood nucleic acid extraction, viral nucleic acid extraction, and others. On the other hand, the services segment is further categorised into custom services and support services. The instrument segments most of the money for this market. These instruments are utterly important in conducting this biopsy.

By End User

On the basis of the end user, the global liquid biopsy products market has been segmented into hospitals/ clinics, pathology laboratories, physician laboratories, academic and research centers, and others. Pathology labs are truly the number one choice of people who want to get fluid biopsy done and this is the reason why the segment makes majority of money for this market.

Region Outlook

On the basis of region, the global liquid biopsy products market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America ranks number one in terms of accumulating money for this market. Higher awareness among patients and advanced healthcare infrastructure in the countries like the United States and Canada helps this market grow here.

Competitive Landscape

The report provides both, qualitative and quantitative research of global liquid biopsy products market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the major players operating in the global liquid biopsy products market are listed below:

Biocept, Inc.
BioChain Institute Inc.
Bio-Rad Laboratories, Inc.
Hoffmann-La Roche Ltd
Genomic Health
Grail Bio, an Illumina spinoff
Guardant Health
MDxHealth
Pathway Genomics
Personal Genome Diagnostics Inc.
QIAGEN
Other Market Participants

Global Liquid Biopsy Products Market

By Application

Circulating tumor cells (CTC) in the blood
Cell free DNA from tumor or fetus cells (in the blood)
Molecular Diagnostics
Early Stage Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Ovarian Cancer
- Others
Non-invasive prenatal tests (NIPT)
Others

By Size

5 ml
50 ml
100 ml
250 ml
Above 250 ml

By Offering

Instruments
- Blood Collection Tube (BCT) for cfDNA and CTCs
- Target Selector Kits
- Cell Free DNA Extraction Kit
- Cell Free Nucleic Acid Extraction Kit
- Mutation Quantification Control Plasma
- Genomic profiling diagnostic kit
- Target Selector NGS Panels
- PCR Purification Kit
- Blood Nucleic Acid Extraction
- Viral Nucleic Acid Extraction
- Others
Reagents
Liquid Biopsy Assays
Tools
Services
- Custom Services
- Support Services
Others

By End User

Hospitals/ Clinics
Pathology Laboratories
Physician Laboratories
Academic and Research Centers
Others

By Region

North America
- U.S
- Canada
- Mexico
- Rest of North America
Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
  - Denmark
  - Finland
  - Iceland
  - Sweden
  - Norway
- Benelux Union
  - Belgium
  - The Netherlands
  - Luxembourg
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
  - Indonesia
  - Thailand
  - Malaysia
  - Singapore
  - Rest of Southeast Asia
- Rest of Asia Pacific
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2020

1.2.2. Base Year: 2021

1.2.3. Forecast Years: 2022 – 2030

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Liquid Biopsy Products Market

6. Market Synopsis: Liquid Biopsy Products Market

7. Liquid Biopsy Products Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Liquid Biopsy Products Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Liquid Biopsy Products Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on Liquid Biopsy Products Market

8. Global Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

8.1. Overview

8.1.1. Global Liquid Biopsy Products Market Revenue (US$ Mn)

8.2. Global Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

8.2.1. Circulating Tumor Cells (CTC) in the Blood

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2015 – 2021

8.2.1.3. Market Forecast, 2022 – 2030

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2015 – 2021

8.2.1.5.1.2. Market Forecast, 2022 – 2030

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2015 – 2021

8.2.1.5.2.2. Market Forecast, 2022 – 2030

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 – 2021

8.2.1.5.3.2. Market Forecast, 2022 – 2030

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 – 2021

8.2.1.5.4.2. Market Forecast, 2022 – 2030

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2015 – 2021

8.2.1.5.5.2. Market Forecast, 2022 – 2030

8.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2015 – 2021

8.2.2.3. Market Forecast, 2022 – 2030

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2015 – 2021

8.2.2.5.1.2. Market Forecast, 2022 – 2030

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2015 – 2021

8.2.2.5.2.2. Market Forecast, 2022 – 2030

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 – 2021

8.2.2.5.3.2. Market Forecast, 2022 – 2030

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 – 2021

8.2.2.5.4.2. Market Forecast, 2022 – 2030

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2015 – 2021

8.2.2.5.5.2. Market Forecast, 2022 – 2030

8.2.3. Molecular Diagnostics

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2015 – 2021

8.2.3.3. Market Forecast, 2022 – 2030

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2015 – 2021

8.2.3.5.1.2. Market Forecast, 2022 – 2030

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2015 – 2021

8.2.3.5.2.2. Market Forecast, 2022 – 2030

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 – 2021

8.2.3.5.3.2. Market Forecast, 2022 – 2030

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 – 2021

8.2.3.5.4.2. Market Forecast, 2022 – 2030

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2015 – 2021

8.2.3.5.5.2. Market Forecast, 2022 – 2030

8.2.4. Early Stage Cancer (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Ovarian Cancer, Others)

8.2.4.1. Lung Cancer

8.2.4.2. Breast Cancer

8.2.4.3. Colorectal Cancer

8.2.4.4. Gastric Cancer

8.2.4.5. Prostate Cancer

8.2.4.6. Liver Cancer

8.2.4.7. Bladder Cancer

8.2.4.8. Ovarian Cancer

8.2.4.9. Others

8.2.5. Non-invasive Prenatal Tests (NIPT)

8.2.5.1. Definition

8.2.5.2. Market Estimation and Penetration, 2015 – 2021

8.2.5.3. Market Forecast, 2022 – 2030

8.2.5.4. Compound Annual Growth Rate (CAGR)

8.2.5.5. Regional Bifurcation

8.2.5.5.1. North America

8.2.5.5.1.1. Market Estimation, 2015 – 2021

8.2.5.5.1.2. Market Forecast, 2022 – 2030

8.2.5.5.2. Europe

8.2.5.5.2.1. Market Estimation, 2015 – 2021

8.2.5.5.2.2. Market Forecast, 2022 – 2030

8.2.5.5.3. Asia Pacific

8.2.5.5.3.1. Market Estimation, 2015 – 2021

8.2.5.5.3.2. Market Forecast, 2022 – 2030

8.2.5.5.4. Middle East and Africa

8.2.5.5.4.1. Market Estimation, 2015 – 2021

8.2.5.5.4.2. Market Forecast, 2022 – 2030

8.2.5.5.5. Latin America

8.2.5.5.5.1. Market Estimation, 2015 – 2021

8.2.5.5.5.2. Market Forecast, 2022 – 2030

8.2.6. Others

8.2.6.1. Definition

8.2.6.2. Market Estimation and Penetration, 2015 – 2021

8.2.6.3. Market Forecast, 2022 – 2030

8.2.6.4. Compound Annual Growth Rate (CAGR)

8.2.6.5. Regional Bifurcation

8.2.6.5.1. North America

8.2.6.5.1.1. Market Estimation, 2015 – 2021

8.2.6.5.1.2. Market Forecast, 2022 – 2030

8.2.6.5.2. Europe

8.2.6.5.2.1. Market Estimation, 2015 – 2021

8.2.6.5.2.2. Market Forecast, 2022 – 2030

8.2.6.5.3. Asia Pacific

8.2.6.5.3.1. Market Estimation, 2015 – 2021

8.2.6.5.3.2. Market Forecast, 2022 – 2030

8.2.6.5.4. Middle East and Africa

8.2.6.5.4.1. Market Estimation, 2015 – 2021

8.2.6.5.4.2. Market Forecast, 2022 – 2030

8.2.6.5.5. Latin America

8.2.6.5.5.1. Market Estimation, 2015 – 2021

8.2.6.5.5.2. Market Forecast, 2022 – 2030

8.3. Key Segment for Channeling Investments

8.3.1. By Application

9. Global Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

9.1. Overview

9.2. Global Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

9.2.1. 5 ml

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2015 – 2021

9.2.1.3. Market Forecast, 2022 – 2030

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2015 – 2021

9.2.1.5.1.2. Market Forecast, 2022 – 2030

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2015 – 2021

9.2.1.5.2.2. Market Forecast, 2022 – 2030

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 – 2021

9.2.1.5.3.2. Market Forecast, 2022 – 2030

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 – 2021

9.2.1.5.4.2. Market Forecast, 2022 – 2030

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2015 – 2021

9.2.1.5.5.2. Market Forecast, 2022 – 2030

9.2.2. 50 ml

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2015 – 2021

9.2.2.3. Market Forecast, 2022 – 2030

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2015 – 2021

9.2.2.5.1.2. Market Forecast, 2022 – 2030

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2015 – 2021

9.2.2.5.2.2. Market Forecast, 2022 – 2030

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 – 2021

9.2.2.5.3.2. Market Forecast, 2022 – 2030

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 – 2021

9.2.2.5.4.2. Market Forecast, 2022 – 2030

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2015 – 2021

9.2.2.5.5.2. Market Forecast, 2022 – 2030

9.2.3. 100 ml

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2015 – 2021

9.2.3.3. Market Forecast, 2022 – 2030

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2015 – 2021

9.2.3.5.1.2. Market Forecast, 2022 – 2030

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2015 – 2021

9.2.3.5.2.2. Market Forecast, 2022 – 2030

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 – 2021

9.2.3.5.3.2. Market Forecast, 2022 – 2030

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 – 2021

9.2.3.5.4.2. Market Forecast, 2022 – 2030

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2015 – 2021

9.2.3.5.5.2. Market Forecast, 2022 – 2030

9.2.4. 250 ml

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2015 – 2021

9.2.4.3. Market Forecast, 2022 – 2030

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2015 – 2021

9.2.4.5.1.2. Market Forecast, 2022 – 2030

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2015 – 2021

9.2.4.5.2.2. Market Forecast, 2022 – 2030

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2015 – 2021

9.2.4.5.3.2. Market Forecast, 2022 – 2030

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2015 – 2021

9.2.4.5.4.2. Market Forecast, 2022 – 2030

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2015 – 2021

9.2.4.5.5.2. Market Forecast, 2022 – 2030

9.2.5. Above 250 ml

9.2.5.1. Definition

9.2.5.2. Market Estimation and Penetration, 2015 – 2021

9.2.5.3. Market Forecast, 2022 – 2030

9.2.5.4. Compound Annual Growth Rate (CAGR)

9.2.5.5. Regional Bifurcation

9.2.5.5.1. North America

9.2.5.5.1.1. Market Estimation, 2015 – 2021

9.2.5.5.1.2. Market Forecast, 2022 – 2030

9.2.5.5.2. Europe

9.2.5.5.2.1. Market Estimation, 2015 – 2021

9.2.5.5.2.2. Market Forecast, 2022 – 2030

9.2.5.5.3. Asia Pacific

9.2.5.5.3.1. Market Estimation, 2015 – 2021

9.2.5.5.3.2. Market Forecast, 2022 – 2030

9.2.5.5.4. Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2015 – 2021

9.2.5.5.4.2. Market Forecast, 2022 – 2030

9.2.5.5.5. Latin America

9.2.5.5.5.1. Market Estimation, 2015 – 2021

9.2.5.5.5.2. Market Forecast, 2022 – 2030

9.3. Key Segment for Channeling Investments

9.3.1. By Size

10. Global Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

10.1. Overview

10.2. Global Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

10.2.1. Instruments (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Blood Collection Tube (BCT) for cfDNA and CTCs, Target Selector Kits, Cell Free DNA Extraction Kit, Cell Free Nucleic Acid Extraction Kit, Mutation Quantification Control Plasma, Genomic Profiling Diagnostics kit, Target Selector NGS Panels, PCR Purification Kit, Blood Nucleic Acid Extraction, Viral Nucleic Acid Extraction, Others)

10.2.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

10.2.1.2. Target Selector Kits

10.2.1.3. Cell Free DNA Extraction Kit

10.2.1.4. Cell Free Nucleic Acid Extraction Kit

10.2.1.5. Mutation Quantification Control Plasma

10.2.1.6. Genomic Profiling Diagnostics kit

10.2.1.7. Target Selector NGS Panels

10.2.1.8. PCR Purification Kit

10.2.1.9. Blood Nucleic Acid Extraction

10.2.1.10. Viral Nucleic Acid Extraction

10.2.1.11. Others

10.2.2. Reagents

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2015 – 2021

10.2.2.3. Market Forecast, 2022 – 2030

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2015 – 2021

10.2.2.5.1.2. Market Forecast, 2022 – 2030

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2015 – 2021

10.2.2.5.2.2. Market Forecast, 2022 – 2030

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 – 2021

10.2.2.5.3.2. Market Forecast, 2022 – 2030

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 – 2021

10.2.2.5.4.2. Market Forecast, 2022 – 2030

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2015 – 2021

10.2.2.5.5.2. Market Forecast, 2022 – 2030

10.2.3. Liquid Biopsy Assays

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2015 – 2021

10.2.3.3. Market Forecast, 2022 – 2030

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2015 – 2021

10.2.3.5.1.2. Market Forecast, 2022 – 2030

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2015 – 2021

10.2.3.5.2.2. Market Forecast, 2022 – 2030

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 – 2021

10.2.3.5.3.2. Market Forecast, 2022 – 2030

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 – 2021

10.2.3.5.4.2. Market Forecast, 2022 – 2030

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2015 – 2021

10.2.3.5.5.2. Market Forecast, 2022 – 2030

10.2.4. Tools

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2015 – 2021

10.2.4.3. Market Forecast, 2022 – 2030

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2015 – 2021

10.2.4.5.1.2. Market Forecast, 2022 – 2030

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2015 – 2021

10.2.4.5.2.2. Market Forecast, 2022 – 2030

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 – 2021

10.2.4.5.3.2. Market Forecast, 2022 – 2030

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 – 2021

10.2.4.5.4.2. Market Forecast, 2022 – 2030

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2015 – 2021

10.2.4.5.5.2. Market Forecast, 2022 – 2030

10.2.5. Services (Definition, Market Estimation and Penetration, 2015 – 2021, Market Estimation (2015 – 2021), Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Custom Services, Support Services)

10.2.5.1. Custom Services

10.2.5.2. Support Services

10.2.6. Others

10.2.6.1. Definition

10.2.6.2. Market Estimation and Penetration, 2015 – 2021

10.2.6.3. Market Forecast, 2022 – 2030

10.2.6.4. Compound Annual Growth Rate (CAGR)

10.2.6.5. Regional Bifurcation

10.2.6.5.1. North America

10.2.6.5.1.1. Market Estimation, 2015 – 2021

10.2.6.5.1.2. Market Forecast, 2022 – 2030

10.2.6.5.2. Europe

10.2.6.5.2.1. Market Estimation, 2015 – 2021

10.2.6.5.2.2. Market Forecast, 2022 – 2030

10.2.6.5.3. Asia Pacific

10.2.6.5.3.1. Market Estimation, 2015 – 2021

10.2.6.5.3.2. Market Forecast, 2022 – 2030

10.2.6.5.4. Middle East and Africa

10.2.6.5.4.1. Market Estimation, 2015 – 2021

10.2.6.5.4.2. Market Forecast, 2022 – 2030

10.2.6.5.5. Latin America

10.2.6.5.5.1. Market Estimation, 2015 – 2021

10.2.6.5.5.2. Market Forecast, 2022 – 2030

10.3. Key Segment for Channeling Investments

10.3.1. By Offering

11. Global Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

11.1. Overview

11.2. Global Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

11.2.1. Hospitals/Clinics

11.2.1.1. Definition

11.2.1.2. Market Estimation and Penetration, 2015 – 2021

11.2.1.3. Market Forecast, 2022 – 2030

11.2.1.4. Compound Annual Growth Rate (CAGR)

11.2.1.5. Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2015 – 2021

11.2.1.5.1.2. Market Forecast, 2022 – 2030

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2015 – 2021

11.2.1.5.2.2. Market Forecast, 2022 – 2030

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2015 – 2021

11.2.1.5.3.2. Market Forecast, 2022 – 2030

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2015 – 2021

11.2.1.5.4.2. Market Forecast, 2022 – 2030

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2015 – 2021

11.2.1.5.5.2. Market Forecast, 2022 – 2030

11.2.2. Pathology Laboratories

11.2.2.1. Definition

11.2.2.2. Market Estimation and Penetration, 2015 – 2021

11.2.2.3. Market Forecast, 2022 – 2030

11.2.2.4. Compound Annual Growth Rate (CAGR)

11.2.2.5. Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2015 – 2021

11.2.2.5.1.2. Market Forecast, 2022 – 2030

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2015 – 2021

11.2.2.5.2.2. Market Forecast, 2022 – 2030

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2015 – 2021

11.2.2.5.3.2. Market Forecast, 2022 – 2030

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2015 – 2021

11.2.2.5.4.2. Market Forecast, 2022 – 2030

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2015 – 2021

11.2.2.5.5.2. Market Forecast, 2022 – 2030

11.2.3. Physician Laboratories

11.2.3.1. Definition

11.2.3.2. Market Estimation and Penetration, 2015 – 2021

11.2.3.3. Market Forecast, 2022 – 2030

11.2.3.4. Compound Annual Growth Rate (CAGR)

11.2.3.5. Regional Bifurcation

11.2.3.5.1. North America

11.2.3.5.1.1. Market Estimation, 2015 – 2021

11.2.3.5.1.2. Market Forecast, 2022 – 2030

11.2.3.5.2. Europe

11.2.3.5.2.1. Market Estimation, 2015 – 2021

11.2.3.5.2.2. Market Forecast, 2022 – 2030

11.2.3.5.3. Asia Pacific

11.2.3.5.3.1. Market Estimation, 2015 – 2021

11.2.3.5.3.2. Market Forecast, 2022 – 2030

11.2.3.5.4. Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2015 – 2021

11.2.3.5.4.2. Market Forecast, 2022 – 2030

11.2.3.5.5. Latin America

11.2.3.5.5.1. Market Estimation, 2015 – 2021

11.2.3.5.5.2. Market Forecast, 2022 – 2030

11.2.4. Academic and Research Centers

11.2.4.1. Definition

11.2.4.2. Market Estimation and Penetration, 2015 – 2021

11.2.4.3. Market Forecast, 2022 – 2030

11.2.4.4. Compound Annual Growth Rate (CAGR)

11.2.4.5. Regional Bifurcation

11.2.4.5.1. North America

11.2.4.5.1.1. Market Estimation, 2015 – 2021

11.2.4.5.1.2. Market Forecast, 2022 – 2030

11.2.4.5.2. Europe

11.2.4.5.2.1. Market Estimation, 2015 – 2021

11.2.4.5.2.2. Market Forecast, 2022 – 2030

11.2.4.5.3. Asia Pacific

11.2.4.5.3.1. Market Estimation, 2015 – 2021

11.2.4.5.3.2. Market Forecast, 2022 – 2030

11.2.4.5.4. Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2015 – 2021

11.2.4.5.4.2. Market Forecast, 2022 – 2030

11.2.4.5.5. Latin America

11.2.4.5.5.1. Market Estimation, 2015 – 2021

11.2.4.5.5.2. Market Forecast, 2022 – 2030

11.2.5. Others

11.2.5.1. Definition

11.2.5.2. Market Estimation and Penetration, 2015 – 2021

11.2.5.3. Market Forecast, 2022 – 2030

11.2.5.4. Compound Annual Growth Rate (CAGR)

11.2.5.5. Regional Bifurcation

11.2.5.5.1. North America

11.2.5.5.1.1. Market Estimation, 2015 – 2021

11.2.5.5.1.2. Market Forecast, 2022 – 2030

11.2.5.5.2. Europe

11.2.5.5.2.1. Market Estimation, 2015 – 2021

11.2.5.5.2.2. Market Forecast, 2022 – 2030

11.2.5.5.3. Asia Pacific

11.2.5.5.3.1. Market Estimation, 2015 – 2021

11.2.5.5.3.2. Market Forecast, 2022 – 2030

11.2.5.5.4. Middle East and Africa

11.2.5.5.4.1. Market Estimation, 2015 – 2021

11.2.5.5.4.2. Market Forecast, 2022 – 2030

11.2.5.5.5. Latin America

11.2.5.5.5.1. Market Estimation, 2015 – 2021

11.2.5.5.5.2. Market Forecast, 2022 – 2030

11.3. Key Segment for Channeling Investments

11.3.1. By End User

12. North America Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

12.1. Overview

12.1.1. North America Liquid Biopsy Products Market Revenue (US$ Mn)

12.2. North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

12.2.1. Circulating Tumor Cells (CTC) in the Blood

12.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

12.2.3. Molecular Diagnostics

12.2.4. Early Stage Cancer

12.2.4.1. Lung Cancer

12.2.4.2. Breast Cancer

12.2.4.3. Colorectal Cancer

12.2.4.4. Gastric Cancer

12.2.4.5. Prostate Cancer

12.2.4.6. Liver Cancer

12.2.4.7. Bladder Cancer

12.2.4.8. Ovarian Cancer

12.2.4.9. Others

12.2.5. Non-invasive Prenatal Tests (NIPT)

12.2.6. Others

12.3. North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

12.3.1. 5 ml

12.3.2. 50 ml

12.3.3. 100 ml

12.3.4. 250 ml

12.3.5. Above 250 ml

12.4. North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

12.4.1. Instruments

12.4.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

12.4.1.2. Target Selector Kits

12.4.1.3. Cell Free DNA Extraction Kit

12.4.1.4. Cell Free Nucleic Acid Extraction Kit

12.4.1.5. Mutation Quantification Control Plasma

12.4.1.6. Genomic Profiling Diagnostics kit

12.4.1.7. Target Selector NGS Panels

12.4.1.8. PCR Purification Kit

12.4.1.9. Blood Nucleic Acid Extraction

12.4.1.10. Viral Nucleic Acid Extraction

12.4.1.11. Others

12.4.2. Reagents

12.4.3. Liquid Biopsy Assays

12.4.4. Tools

12.4.5. Services

12.4.5.1. Custom Services

12.4.5.2. Support Services

12.4.6. Others

12.5. North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

12.5.1. Hospitals/Clinics

12.5.2. Pathology Laboratories

12.5.3. Physician Laboratories

12.5.4. Academic and Research Centers

12.5.5. Others

12.6. North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. U.S

12.6.1.1. U.S Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

12.6.1.1.1. Circulating Tumor Cells (CTC) in the Blood

12.6.1.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

12.6.1.1.3. Molecular Diagnostics

12.6.1.1.4. Early Stage Cancer

12.6.1.1.4.1. Lung Cancer

12.6.1.1.4.2. Breast Cancer

12.6.1.1.4.3. Colorectal Cancer

12.6.1.1.4.4. Gastric Cancer

12.6.1.1.4.5. Prostate Cancer

12.6.1.1.4.6. Liver Cancer

12.6.1.1.4.7. Bladder Cancer

12.6.1.1.4.8. Ovarian Cancer

12.6.1.1.4.9. Others

12.6.1.1.5. Non-invasive Prenatal Tests (NIPT)

12.6.1.1.6. Others

12.6.1.2. U.S Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

12.6.1.2.1. 5 ml

12.6.1.2.2. 50 ml

12.6.1.2.3. 100 ml

12.6.1.2.4. 250 ml

12.6.1.2.5. Above 250 ml

12.6.1.3. U.S Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

12.6.1.3.1. Instruments

12.6.1.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

12.6.1.3.1.2. Target Selector Kits

12.6.1.3.1.3. Cell Free DNA Extraction Kit

12.6.1.3.1.4. Cell Free Nucleic Acid Extraction Kit

12.6.1.3.1.5. Mutation Quantification Control Plasma

12.6.1.3.1.6. Genomic Profiling Diagnostics kit

12.6.1.3.1.7. Target Selector NGS Panels

12.6.1.3.1.8. PCR Purification Kit

12.6.1.3.1.9. Blood Nucleic Acid Extraction

12.6.1.3.1.10. Viral Nucleic Acid Extraction

12.6.1.3.1.11. Others

12.6.1.3.2. Reagents

12.6.1.3.3. Liquid Biopsy Assays

12.6.1.3.4. Tools

12.6.1.3.5. Services

12.6.1.3.5.1. Custom Services

12.6.1.3.5.2. Support Services

12.6.1.3.6. Others

12.6.1.4. U.S Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

12.6.1.4.1. Hospitals/Clinics

12.6.1.4.2. Pathology Laboratories

12.6.1.4.3. Physician Laboratories

12.6.1.4.4. Academic and Research Centers

12.6.1.4.5. Others

12.6.2. Canada

12.6.2.1. Canada Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

12.6.2.1.1. Circulating Tumor Cells (CTC) in the Blood

12.6.2.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

12.6.2.1.3. Molecular Diagnostics

12.6.2.1.4. Early Stage Cancer

12.6.2.1.4.1. Lung Cancer

12.6.2.1.4.2. Breast Cancer

12.6.2.1.4.3. Colorectal Cancer

12.6.2.1.4.4. Gastric Cancer

12.6.2.1.4.5. Prostate Cancer

12.6.2.1.4.6. Liver Cancer

12.6.2.1.4.7. Bladder Cancer

12.6.2.1.4.8. Ovarian Cancer

12.6.2.1.4.9. Others

12.6.2.1.5. Non-invasive Prenatal Tests (NIPT)

12.6.2.1.6. Others

12.6.2.2. Canada Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

12.6.2.2.1. 5 ml

12.6.2.2.2. 50 ml

12.6.2.2.3. 100 ml

12.6.2.2.4. 250 ml

12.6.2.2.5. Above 250 ml

12.6.2.3. Canada Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

12.6.2.3.1. Instruments

12.6.2.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

12.6.2.3.1.2. Target Selector Kits

12.6.2.3.1.3. Cell Free DNA Extraction Kit

12.6.2.3.1.4. Cell Free Nucleic Acid Extraction Kit

12.6.2.3.1.5. Mutation Quantification Control Plasma

12.6.2.3.1.6. Genomic Profiling Diagnostics kit

12.6.2.3.1.7. Target Selector NGS Panels

12.6.2.3.1.8. PCR Purification Kit

12.6.2.3.1.9. Blood Nucleic Acid Extraction

12.6.2.3.1.10. Viral Nucleic Acid Extraction

12.6.2.3.1.11. Others

12.6.2.3.2. Reagents

12.6.2.3.3. Liquid Biopsy Assays

12.6.2.3.4. Tools

12.6.2.3.5. Services

12.6.2.3.5.1. Custom Services

12.6.2.3.5.2. Support Services

12.6.2.3.6. Others

12.6.2.4. Canada Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

12.6.2.4.1. Hospitals/Clinics

12.6.2.4.2. Pathology Laboratories

12.6.2.4.3. Physician Laboratories

12.6.2.4.4. Academic and Research Centers

12.6.2.4.5. Others

12.6.3. Mexico

12.6.3.1. Mexico Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

12.6.3.1.1. Circulating Tumor Cells (CTC) in the Blood

12.6.3.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

12.6.3.1.3. Molecular Diagnostics

12.6.3.1.4. Early Stage Cancer

12.6.3.1.4.1. Lung Cancer

12.6.3.1.4.2. Breast Cancer

12.6.3.1.4.3. Colorectal Cancer

12.6.3.1.4.4. Gastric Cancer

12.6.3.1.4.5. Prostate Cancer

12.6.3.1.4.6. Liver Cancer

12.6.3.1.4.7. Bladder Cancer

12.6.3.1.4.8. Ovarian Cancer

12.6.3.1.4.9. Others

12.6.3.1.5. Non-invasive Prenatal Tests (NIPT)

12.6.3.1.6. Others

12.6.3.2. Mexico Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

12.6.3.2.1. 5 ml

12.6.3.2.2. 50 ml

12.6.3.2.3. 100 ml

12.6.3.2.4. 250 ml

12.6.3.2.5. Above 250 ml

12.6.3.3. Mexico Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

12.6.3.3.1. Instruments

12.6.3.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

12.6.3.3.1.2. Target Selector Kits

12.6.3.3.1.3. Cell Free DNA Extraction Kit

12.6.3.3.1.4. Cell Free Nucleic Acid Extraction Kit

12.6.3.3.1.5. Mutation Quantification Control Plasma

12.6.3.3.1.6. Genomic Profiling Diagnostics kit

12.6.3.3.1.7. Target Selector NGS Panels

12.6.3.3.1.8. PCR Purification Kit

12.6.3.3.1.9. Blood Nucleic Acid Extraction

12.6.3.3.1.10. Viral Nucleic Acid Extraction

12.6.3.3.1.11. Others

12.6.3.3.2. Reagents

12.6.3.3.3. Liquid Biopsy Assays

12.6.3.3.4. Tools

12.6.3.3.5. Services

12.6.3.3.5.1. Custom Services

12.6.3.3.5.2. Support Services

12.6.3.3.6. Others

12.6.3.4. Mexico Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

12.6.3.4.1. Hospitals/Clinics

12.6.3.4.2. Pathology Laboratories

12.6.3.4.3. Physician Laboratories

12.6.3.4.4. Academic and Research Centers

12.6.3.4.5. Others

12.6.4. Rest of North America

12.6.4.1. Rest of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

12.6.4.1.1. Circulating Tumor Cells (CTC) in the Blood

12.6.4.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

12.6.4.1.3. Molecular Diagnostics

12.6.4.1.4. Early Stage Cancer

12.6.4.1.4.1. Lung Cancer

12.6.4.1.4.2. Breast Cancer

12.6.4.1.4.3. Colorectal Cancer

12.6.4.1.4.4. Gastric Cancer

12.6.4.1.4.5. Prostate Cancer

12.6.4.1.4.6. Liver Cancer

12.6.4.1.4.7. Bladder Cancer

12.6.4.1.4.8. Ovarian Cancer

12.6.4.1.4.9. Others

12.6.4.1.5. Non-invasive Prenatal Tests (NIPT)

12.6.4.1.6. Others

12.6.4.2. Rest of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

12.6.4.2.1. 5 ml

12.6.4.2.2. 50 ml

12.6.4.2.3. 100 ml

12.6.4.2.4. 250 ml

12.6.4.2.5. Above 250 ml

12.6.4.3. Rest of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

12.6.4.3.1. Instruments

12.6.4.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

12.6.4.3.1.2. Target Selector Kits

12.6.4.3.1.3. Cell Free DNA Extraction Kit

12.6.4.3.1.4. Cell Free Nucleic Acid Extraction Kit

12.6.4.3.1.5. Mutation Quantification Control Plasma

12.6.4.3.1.6. Genomic Profiling Diagnostics kit

12.6.4.3.1.7. Target Selector NGS Panels

12.6.4.3.1.8. PCR Purification Kit

12.6.4.3.1.9. Blood Nucleic Acid Extraction

12.6.4.3.1.10. Viral Nucleic Acid Extraction

12.6.4.3.1.11. Others

12.6.4.3.2. Reagents

12.6.4.3.3. Liquid Biopsy Assays

12.6.4.3.4. Tools

12.6.4.3.5. Services

12.6.4.3.5.1. Custom Services

12.6.4.3.5.2. Support Services

12.6.4.3.6. Others

12.6.4.4. Rest of North America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

12.6.4.4.1. Hospitals/Clinics

12.6.4.4.2. Pathology Laboratories

12.6.4.4.3. Physician Laboratories

12.6.4.4.4. Academic and Research Centers

12.6.4.4.5. Others

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Application

12.7.3. By Size

12.7.4. By Offering

12.7.5. By End User

13. Europe Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

13.1. Overview

13.1.1. Europe Liquid Biopsy Products Market Revenue (US$ Mn)

13.2. Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.2.1. Circulating Tumor Cells (CTC) in the Blood

13.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.2.3. Molecular Diagnostics

13.2.4. Early Stage Cancer

13.2.4.1. Lung Cancer

13.2.4.2. Breast Cancer

13.2.4.3. Colorectal Cancer

13.2.4.4. Gastric Cancer

13.2.4.5. Prostate Cancer

13.2.4.6. Liver Cancer

13.2.4.7. Bladder Cancer

13.2.4.8. Ovarian Cancer

13.2.4.9. Others

13.2.5. Non-invasive Prenatal Tests (NIPT)

13.2.6. Others

13.3. Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.3.1. 5 ml

13.3.2. 50 ml

13.3.3. 100 ml

13.3.4. 250 ml

13.3.5. Above 250 ml

13.4. Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.4.1. Instruments

13.4.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.4.1.2. Target Selector Kits

13.4.1.3. Cell Free DNA Extraction Kit

13.4.1.4. Cell Free Nucleic Acid Extraction Kit

13.4.1.5. Mutation Quantification Control Plasma

13.4.1.6. Genomic Profiling Diagnostics kit

13.4.1.7. Target Selector NGS Panels

13.4.1.8. PCR Purification Kit

13.4.1.9. Blood Nucleic Acid Extraction

13.4.1.10. Viral Nucleic Acid Extraction

13.4.1.11. Others

13.4.2. Reagents

13.4.3. Liquid Biopsy Assays

13.4.4. Tools

13.4.5. Services

13.4.5.1. Custom Services

13.4.5.2. Support Services

13.4.6. Others

13.5. Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.5.1. Hospitals/Clinics

13.5.2. Pathology Laboratories

13.5.3. Physician Laboratories

13.5.4. Academic and Research Centers

13.5.5. Others

13.6. Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. France

13.6.1.1. France Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.1.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.1.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.1.1.3. Molecular Diagnostics

13.6.1.1.4. Early Stage Cancer

13.6.1.1.4.1. Lung Cancer

13.6.1.1.4.2. Breast Cancer

13.6.1.1.4.3. Colorectal Cancer

13.6.1.1.4.4. Gastric Cancer

13.6.1.1.4.5. Prostate Cancer

13.6.1.1.4.6. Liver Cancer

13.6.1.1.4.7. Bladder Cancer

13.6.1.1.4.8. Ovarian Cancer

13.6.1.1.4.9. Others

13.6.1.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.1.1.6. Others

13.6.1.2. France Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.1.2.1. 5 ml

13.6.1.2.2. 50 ml

13.6.1.2.3. 100 ml

13.6.1.2.4. 250 ml

13.6.1.2.5. Above 250 ml

13.6.1.3. France Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.1.3.1. Instruments

13.6.1.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.1.3.1.2. Target Selector Kits

13.6.1.3.1.3. Cell Free DNA Extraction Kit

13.6.1.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.1.3.1.5. Mutation Quantification Control Plasma

13.6.1.3.1.6. Genomic Profiling Diagnostics kit

13.6.1.3.1.7. Target Selector NGS Panels

13.6.1.3.1.8. PCR Purification Kit

13.6.1.3.1.9. Blood Nucleic Acid Extraction

13.6.1.3.1.10. Viral Nucleic Acid Extraction

13.6.1.3.1.11. Others

13.6.1.3.2. Reagents

13.6.1.3.3. Liquid Biopsy Assays

13.6.1.3.4. Tools

13.6.1.3.5. Services

13.6.1.3.5.1. Custom Services

13.6.1.3.5.2. Support Services

13.6.1.3.6. Others

13.6.1.4. France Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.1.4.1. Hospitals/Clinics

13.6.1.4.2. Pathology Laboratories

13.6.1.4.3. Physician Laboratories

13.6.1.4.4. Academic and Research Centers

13.6.1.4.5. Others

13.6.2. The UK

13.6.2.1. The UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.2.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.2.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.2.1.3. Molecular Diagnostics

13.6.2.1.4. Early Stage Cancer

13.6.2.1.4.1. Lung Cancer

13.6.2.1.4.2. Breast Cancer

13.6.2.1.4.3. Colorectal Cancer

13.6.2.1.4.4. Gastric Cancer

13.6.2.1.4.5. Prostate Cancer

13.6.2.1.4.6. Liver Cancer

13.6.2.1.4.7. Bladder Cancer

13.6.2.1.4.8. Ovarian Cancer

13.6.2.1.4.9. Others

13.6.2.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.2.1.6. Others

13.6.2.2. The UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.2.2.1. 5 ml

13.6.2.2.2. 50 ml

13.6.2.2.3. 100 ml

13.6.2.2.4. 250 ml

13.6.2.2.5. Above 250 ml

13.6.2.3. The UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.2.3.1. Instruments

13.6.2.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.2.3.1.2. Target Selector Kits

13.6.2.3.1.3. Cell Free DNA Extraction Kit

13.6.2.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.2.3.1.5. Mutation Quantification Control Plasma

13.6.2.3.1.6. Genomic Profiling Diagnostics kit

13.6.2.3.1.7. Target Selector NGS Panels

13.6.2.3.1.8. PCR Purification Kit

13.6.2.3.1.9. Blood Nucleic Acid Extraction

13.6.2.3.1.10. Viral Nucleic Acid Extraction

13.6.2.3.1.11. Others

13.6.2.3.2. Reagents

13.6.2.3.3. Liquid Biopsy Assays

13.6.2.3.4. Tools

13.6.2.3.5. Services

13.6.2.3.5.1. Custom Services

13.6.2.3.5.2. Support Services

13.6.2.3.6. Others

13.6.2.4. The UK Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.2.4.1. Hospitals/Clinics

13.6.2.4.2. Pathology Laboratories

13.6.2.4.3. Physician Laboratories

13.6.2.4.4. Academic and Research Centers

13.6.2.4.5. Others

13.6.3. Spain

13.6.3.1. Spain Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.3.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.3.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.3.1.3. Molecular Diagnostics

13.6.3.1.4. Early Stage Cancer

13.6.3.1.4.1. Lung Cancer

13.6.3.1.4.2. Breast Cancer

13.6.3.1.4.3. Colorectal Cancer

13.6.3.1.4.4. Gastric Cancer

13.6.3.1.4.5. Prostate Cancer

13.6.3.1.4.6. Liver Cancer

13.6.3.1.4.7. Bladder Cancer

13.6.3.1.4.8. Ovarian Cancer

13.6.3.1.4.9. Others

13.6.3.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.3.1.6. Others

13.6.3.2. Spain Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.3.2.1. 5 ml

13.6.3.2.2. 50 ml

13.6.3.2.3. 100 ml

13.6.3.2.4. 250 ml

13.6.3.2.5. Above 250 ml

13.6.3.3. Spain Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.3.3.1. Instruments

13.6.3.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.3.3.1.2. Target Selector Kits

13.6.3.3.1.3. Cell Free DNA Extraction Kit

13.6.3.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.3.3.1.5. Mutation Quantification Control Plasma

13.6.3.3.1.6. Genomic Profiling Diagnostics kit

13.6.3.3.1.7. Target Selector NGS Panels

13.6.3.3.1.8. PCR Purification Kit

13.6.3.3.1.9. Blood Nucleic Acid Extraction

13.6.3.3.1.10. Viral Nucleic Acid Extraction

13.6.3.3.1.11. Others

13.6.3.3.2. Reagents

13.6.3.3.3. Liquid Biopsy Assays

13.6.3.3.4. Tools

13.6.3.3.5. Services

13.6.3.3.5.1. Custom Services

13.6.3.3.5.2. Support Services

13.6.3.3.6. Others

13.6.3.4. Spain Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.3.4.1. Hospitals/Clinics

13.6.3.4.2. Pathology Laboratories

13.6.3.4.3. Physician Laboratories

13.6.3.4.4. Academic and Research Centers

13.6.3.4.5. Others

13.6.4. Germany

13.6.4.1. Germany Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.4.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.4.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.4.1.3. Molecular Diagnostics

13.6.4.1.4. Early Stage Cancer

13.6.4.1.4.1. Lung Cancer

13.6.4.1.4.2. Breast Cancer

13.6.4.1.4.3. Colorectal Cancer

13.6.4.1.4.4. Gastric Cancer

13.6.4.1.4.5. Prostate Cancer

13.6.4.1.4.6. Liver Cancer

13.6.4.1.4.7. Bladder Cancer

13.6.4.1.4.8. Ovarian Cancer

13.6.4.1.4.9. Others

13.6.4.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.4.1.6. Others

13.6.4.2. Germany Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.4.2.1. 5 ml

13.6.4.2.2. 50 ml

13.6.4.2.3. 100 ml

13.6.4.2.4. 250 ml

13.6.4.2.5. Above 250 ml

13.6.4.3. Germany Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.4.3.1. Instruments

13.6.4.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.4.3.1.2. Target Selector Kits

13.6.4.3.1.3. Cell Free DNA Extraction Kit

13.6.4.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.4.3.1.5. Mutation Quantification Control Plasma

13.6.4.3.1.6. Genomic Profiling Diagnostics kit

13.6.4.3.1.7. Target Selector NGS Panels

13.6.4.3.1.8. PCR Purification Kit

13.6.4.3.1.9. Blood Nucleic Acid Extraction

13.6.4.3.1.10. Viral Nucleic Acid Extraction

13.6.4.3.1.11. Others

13.6.4.3.2. Reagents

13.6.4.3.3. Liquid Biopsy Assays

13.6.4.3.4. Tools

13.6.4.3.5. Services

13.6.4.3.5.1. Custom Services

13.6.4.3.5.2. Support Services

13.6.4.3.6. Others

13.6.4.4. Germany Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.4.4.1. Hospitals/Clinics

13.6.4.4.2. Pathology Laboratories

13.6.4.4.3. Physician Laboratories

13.6.4.4.4. Academic and Research Centers

13.6.4.4.5. Others

13.6.5. Italy

13.6.5.1. Italy Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.5.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.5.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.5.1.3. Molecular Diagnostics

13.6.5.1.4. Early Stage Cancer

13.6.5.1.4.1. Lung Cancer

13.6.5.1.4.2. Breast Cancer

13.6.5.1.4.3. Colorectal Cancer

13.6.5.1.4.4. Gastric Cancer

13.6.5.1.4.5. Prostate Cancer

13.6.5.1.4.6. Liver Cancer

13.6.5.1.4.7. Bladder Cancer

13.6.5.1.4.8. Ovarian Cancer

13.6.5.1.4.9. Others

13.6.5.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.5.1.6. Others

13.6.5.2. Italy Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.5.2.1. 5 ml

13.6.5.2.2. 50 ml

13.6.5.2.3. 100 ml

13.6.5.2.4. 250 ml

13.6.5.2.5. Above 250 ml

13.6.5.3. Italy Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.5.3.1. Instruments

13.6.5.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.5.3.1.2. Target Selector Kits

13.6.5.3.1.3. Cell Free DNA Extraction Kit

13.6.5.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.5.3.1.5. Mutation Quantification Control Plasma

13.6.5.3.1.6. Genomic Profiling Diagnostics kit

13.6.5.3.1.7. Target Selector NGS Panels

13.6.5.3.1.8. PCR Purification Kit

13.6.5.3.1.9. Blood Nucleic Acid Extraction

13.6.5.3.1.10. Viral Nucleic Acid Extraction

13.6.5.3.1.11. Others

13.6.5.3.2. Reagents

13.6.5.3.3. Liquid Biopsy Assays

13.6.5.3.4. Tools

13.6.5.3.5. Services

13.6.5.3.5.1. Custom Services

13.6.5.3.5.2. Support Services

13.6.5.3.6. Others

13.6.5.4. Italy Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.5.4.1. Hospitals/Clinics

13.6.5.4.2. Pathology Laboratories

13.6.5.4.3. Physician Laboratories

13.6.5.4.4. Academic and Research Centers

13.6.5.4.5. Others

13.6.6. Nordic Countries

13.6.6.1. Nordic Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.6.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.6.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.6.1.3. Molecular Diagnostics

13.6.6.1.4. Early Stage Cancer

13.6.6.1.4.1. Lung Cancer

13.6.6.1.4.2. Breast Cancer

13.6.6.1.4.3. Colorectal Cancer

13.6.6.1.4.4. Gastric Cancer

13.6.6.1.4.5. Prostate Cancer

13.6.6.1.4.6. Liver Cancer

13.6.6.1.4.7. Bladder Cancer

13.6.6.1.4.8. Ovarian Cancer

13.6.6.1.4.9. Others

13.6.6.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.6.1.6. Others

13.6.6.2. Nordic Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.6.2.1. 5 ml

13.6.6.2.2. 50 ml

13.6.6.2.3. 100 ml

13.6.6.2.4. 250 ml

13.6.6.2.5. Above 250 ml

13.6.6.3. Nordic Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.6.3.1. Instruments

13.6.6.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.6.3.1.2. Target Selector Kits

13.6.6.3.1.3. Cell Free DNA Extraction Kit

13.6.6.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.6.3.1.5. Mutation Quantification Control Plasma

13.6.6.3.1.6. Genomic Profiling Diagnostics kit

13.6.6.3.1.7. Target Selector NGS Panels

13.6.6.3.1.8. PCR Purification Kit

13.6.6.3.1.9. Blood Nucleic Acid Extraction

13.6.6.3.1.10. Viral Nucleic Acid Extraction

13.6.6.3.1.11. Others

13.6.6.3.2. Reagents

13.6.6.3.3. Liquid Biopsy Assays

13.6.6.3.4. Tools

13.6.6.3.5. Services

13.6.6.3.5.1. Custom Services

13.6.6.3.5.2. Support Services

13.6.6.3.6. Others

13.6.6.4. Nordic Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.6.4.1. Hospitals/Clinics

13.6.6.4.2. Pathology Laboratories

13.6.6.4.3. Physician Laboratories

13.6.6.4.4. Academic and Research Centers

13.6.6.4.5. Others

13.6.6.5. Nordic Countries Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

13.6.6.5.1. Denmark

13.6.6.5.2. Finland

13.6.6.5.3. Iceland

13.6.6.5.4. Sweden

13.6.6.5.5. Norway

13.6.7. Benelux Union

13.6.7.1. Benelux Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.7.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.7.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.7.1.3. Molecular Diagnostics

13.6.7.1.4. Early Stage Cancer

13.6.7.1.4.1. Lung Cancer

13.6.7.1.4.2. Breast Cancer

13.6.7.1.4.3. Colorectal Cancer

13.6.7.1.4.4. Gastric Cancer

13.6.7.1.4.5. Prostate Cancer

13.6.7.1.4.6. Liver Cancer

13.6.7.1.4.7. Bladder Cancer

13.6.7.1.4.8. Ovarian Cancer

13.6.7.1.4.9. Others

13.6.7.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.7.1.6. Others

13.6.7.2. Benelux Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.7.2.1. 5 ml

13.6.7.2.2. 50 ml

13.6.7.2.3. 100 ml

13.6.7.2.4. 250 ml

13.6.7.2.5. Above 250 ml

13.6.7.3. Benelux Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.7.3.1. Instruments

13.6.7.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.7.3.1.2. Target Selector Kits

13.6.7.3.1.3. Cell Free DNA Extraction Kit

13.6.7.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.7.3.1.5. Mutation Quantification Control Plasma

13.6.7.3.1.6. Genomic Profiling Diagnostics kit

13.6.7.3.1.7. Target Selector NGS Panels

13.6.7.3.1.8. PCR Purification Kit

13.6.7.3.1.9. Blood Nucleic Acid Extraction

13.6.7.3.1.10. Viral Nucleic Acid Extraction

13.6.7.3.1.11. Others

13.6.7.3.2. Reagents

13.6.7.3.3. Liquid Biopsy Assays

13.6.7.3.4. Tools

13.6.7.3.5. Services

13.6.7.3.5.1. Custom Services

13.6.7.3.5.2. Support Services

13.6.7.3.6. Others

13.6.7.4. Benelux Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.7.4.1. Hospitals/Clinics

13.6.7.4.2. Pathology Laboratories

13.6.7.4.3. Physician Laboratories

13.6.7.4.4. Academic and Research Centers

13.6.7.4.5. Others

13.6.7.5. Benelux Union Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

13.6.7.5.1. Belgium

13.6.7.5.2. The Netherlands

13.6.7.5.3. Luxembourg

13.6.8. Rest of Europe

13.6.8.1. Rest of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

13.6.8.1.1. Circulating Tumor Cells (CTC) in the Blood

13.6.8.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

13.6.8.1.3. Molecular Diagnostics

13.6.8.1.4. Early Stage Cancer

13.6.8.1.4.1. Lung Cancer

13.6.8.1.4.2. Breast Cancer

13.6.8.1.4.3. Colorectal Cancer

13.6.8.1.4.4. Gastric Cancer

13.6.8.1.4.5. Prostate Cancer

13.6.8.1.4.6. Liver Cancer

13.6.8.1.4.7. Bladder Cancer

13.6.8.1.4.8. Ovarian Cancer

13.6.8.1.4.9. Others

13.6.8.1.5. Non-invasive Prenatal Tests (NIPT)

13.6.8.1.6. Others

13.6.8.2. Rest of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

13.6.8.2.1. 5 ml

13.6.8.2.2. 50 ml

13.6.8.2.3. 100 ml

13.6.8.2.4. 250 ml

13.6.8.2.5. Above 250 ml

13.6.8.3. Rest of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

13.6.8.3.1. Instruments

13.6.8.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

13.6.8.3.1.2. Target Selector Kits

13.6.8.3.1.3. Cell Free DNA Extraction Kit

13.6.8.3.1.4. Cell Free Nucleic Acid Extraction Kit

13.6.8.3.1.5. Mutation Quantification Control Plasma

13.6.8.3.1.6. Genomic Profiling Diagnostics kit

13.6.8.3.1.7. Target Selector NGS Panels

13.6.8.3.1.8. PCR Purification Kit

13.6.8.3.1.9. Blood Nucleic Acid Extraction

13.6.8.3.1.10. Viral Nucleic Acid Extraction

13.6.8.3.1.11. Others

13.6.8.3.2. Reagents

13.6.8.3.3. Liquid Biopsy Assays

13.6.8.3.4. Tools

13.6.8.3.5. Services

13.6.8.3.5.1. Custom Services

13.6.8.3.5.2. Support Services

13.6.8.3.6. Others

13.6.8.4. Rest of Europe Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

13.6.8.4.1. Hospitals/Clinics

13.6.8.4.2. Pathology Laboratories

13.6.8.4.3. Physician Laboratories

13.6.8.4.4. Academic and Research Centers

13.6.8.4.5. Others

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Application

13.7.3. By Size

13.7.4. By Offering

13.7.5. By End User

14. Asia Pacific Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

14.1. Overview

14.1.1. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn)

14.2. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.2.1. Circulating Tumor Cells (CTC) in the Blood

14.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.2.3. Molecular Diagnostics

14.2.4. Early Stage Cancer

14.2.4.1. Lung Cancer

14.2.4.2. Breast Cancer

14.2.4.3. Colorectal Cancer

14.2.4.4. Gastric Cancer

14.2.4.5. Prostate Cancer

14.2.4.6. Liver Cancer

14.2.4.7. Bladder Cancer

14.2.4.8. Ovarian Cancer

14.2.4.9. Others

14.2.5. Non-invasive Prenatal Tests (NIPT)

14.2.6. Others

14.3. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.3.1. 5 ml

14.3.2. 50 ml

14.3.3. 100 ml

14.3.4. 250 ml

14.3.5. Above 250 ml

14.4. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.4.1. Instruments

14.4.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.4.1.2. Target Selector Kits

14.4.1.3. Cell Free DNA Extraction Kit

14.4.1.4. Cell Free Nucleic Acid Extraction Kit

14.4.1.5. Mutation Quantification Control Plasma

14.4.1.6. Genomic Profiling Diagnostics kit

14.4.1.7. Target Selector NGS Panels

14.4.1.8. PCR Purification Kit

14.4.1.9. Blood Nucleic Acid Extraction

14.4.1.10. Viral Nucleic Acid Extraction

14.4.1.11. Others

14.4.2. Reagents

14.4.3. Liquid Biopsy Assays

14.4.4. Tools

14.4.5. Services

14.4.5.1. Custom Services

14.4.5.2. Support Services

14.4.6. Others

14.5. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.5.1. Hospitals/Clinics

14.5.2. Pathology Laboratories

14.5.3. Physician Laboratories

14.5.4. Academic and Research Centers

14.5.5. Others

14.6. Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

14.6.1. China

14.6.1.1. China Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.1.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.1.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.1.1.3. Molecular Diagnostics

14.6.1.1.4. Early Stage Cancer

14.6.1.1.4.1. Lung Cancer

14.6.1.1.4.2. Breast Cancer

14.6.1.1.4.3. Colorectal Cancer

14.6.1.1.4.4. Gastric Cancer

14.6.1.1.4.5. Prostate Cancer

14.6.1.1.4.6. Liver Cancer

14.6.1.1.4.7. Bladder Cancer

14.6.1.1.4.8. Ovarian Cancer

14.6.1.1.4.9. Others

14.6.1.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.1.1.6. Others

14.6.1.2. China Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.1.2.1. 5 ml

14.6.1.2.2. 50 ml

14.6.1.2.3. 100 ml

14.6.1.2.4. 250 ml

14.6.1.2.5. Above 250 ml

14.6.1.3. China Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.1.3.1. Instruments

14.6.1.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.1.3.1.2. Target Selector Kits

14.6.1.3.1.3. Cell Free DNA Extraction Kit

14.6.1.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.1.3.1.5. Mutation Quantification Control Plasma

14.6.1.3.1.6. Genomic Profiling Diagnostics kit

14.6.1.3.1.7. Target Selector NGS Panels

14.6.1.3.1.8. PCR Purification Kit

14.6.1.3.1.9. Blood Nucleic Acid Extraction

14.6.1.3.1.10. Viral Nucleic Acid Extraction

14.6.1.3.1.11. Others

14.6.1.3.2. Reagents

14.6.1.3.3. Liquid Biopsy Assays

14.6.1.3.4. Tools

14.6.1.3.5. Services

14.6.1.3.5.1. Custom Services

14.6.1.3.5.2. Support Services

14.6.1.3.6. Others

14.6.1.4. China Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.1.4.1. Hospitals/Clinics

14.6.1.4.2. Pathology Laboratories

14.6.1.4.3. Physician Laboratories

14.6.1.4.4. Academic and Research Centers

14.6.1.4.5. Others

14.6.2. Japan

14.6.2.1. Japan Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.2.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.2.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.2.1.3. Molecular Diagnostics

14.6.2.1.4. Early Stage Cancer

14.6.2.1.4.1. Lung Cancer

14.6.2.1.4.2. Breast Cancer

14.6.2.1.4.3. Colorectal Cancer

14.6.2.1.4.4. Gastric Cancer

14.6.2.1.4.5. Prostate Cancer

14.6.2.1.4.6. Liver Cancer

14.6.2.1.4.7. Bladder Cancer

14.6.2.1.4.8. Ovarian Cancer

14.6.2.1.4.9. Others

14.6.2.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.2.1.6. Others

14.6.2.2. Japan Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.2.2.1. 5 ml

14.6.2.2.2. 50 ml

14.6.2.2.3. 100 ml

14.6.2.2.4. 250 ml

14.6.2.2.5. Above 250 ml

14.6.2.3. Japan Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.2.3.1. Instruments

14.6.2.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.2.3.1.2. Target Selector Kits

14.6.2.3.1.3. Cell Free DNA Extraction Kit

14.6.2.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.2.3.1.5. Mutation Quantification Control Plasma

14.6.2.3.1.6. Genomic Profiling Diagnostics kit

14.6.2.3.1.7. Target Selector NGS Panels

14.6.2.3.1.8. PCR Purification Kit

14.6.2.3.1.9. Blood Nucleic Acid Extraction

14.6.2.3.1.10. Viral Nucleic Acid Extraction

14.6.2.3.1.11. Others

14.6.2.3.2. Reagents

14.6.2.3.3. Liquid Biopsy Assays

14.6.2.3.4. Tools

14.6.2.3.5. Services

14.6.2.3.5.1. Custom Services

14.6.2.3.5.2. Support Services

14.6.2.3.6. Others

14.6.2.4. Japan Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.2.4.1. Hospitals/Clinics

14.6.2.4.2. Pathology Laboratories

14.6.2.4.3. Physician Laboratories

14.6.2.4.4. Academic and Research Centers

14.6.2.4.5. Others

14.6.3. India

14.6.3.1. India Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.3.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.3.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.3.1.3. Molecular Diagnostics

14.6.3.1.4. Early Stage Cancer

14.6.3.1.4.1. Lung Cancer

14.6.3.1.4.2. Breast Cancer

14.6.3.1.4.3. Colorectal Cancer

14.6.3.1.4.4. Gastric Cancer

14.6.3.1.4.5. Prostate Cancer

14.6.3.1.4.6. Liver Cancer

14.6.3.1.4.7. Bladder Cancer

14.6.3.1.4.8. Ovarian Cancer

14.6.3.1.4.9. Others

14.6.3.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.3.1.6. Others

14.6.3.2. India Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.3.2.1. 5 ml

14.6.3.2.2. 50 ml

14.6.3.2.3. 100 ml

14.6.3.2.4. 250 ml

14.6.3.2.5. Above 250 ml

14.6.3.3. India Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.3.3.1. Instruments

14.6.3.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.3.3.1.2. Target Selector Kits

14.6.3.3.1.3. Cell Free DNA Extraction Kit

14.6.3.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.3.3.1.5. Mutation Quantification Control Plasma

14.6.3.3.1.6. Genomic Profiling Diagnostics kit

14.6.3.3.1.7. Target Selector NGS Panels

14.6.3.3.1.8. PCR Purification Kit

14.6.3.3.1.9. Blood Nucleic Acid Extraction

14.6.3.3.1.10. Viral Nucleic Acid Extraction

14.6.3.3.1.11. Others

14.6.3.3.2. Reagents

14.6.3.3.3. Liquid Biopsy Assays

14.6.3.3.4. Tools

14.6.3.3.5. Services

14.6.3.3.5.1. Custom Services

14.6.3.3.5.2. Support Services

14.6.3.3.6. Others

14.6.3.4. India Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.3.4.1. Hospitals/Clinics

14.6.3.4.2. Pathology Laboratories

14.6.3.4.3. Physician Laboratories

14.6.3.4.4. Academic and Research Centers

14.6.3.4.5. Others

14.6.4. New Zealand

14.6.4.1. New Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.4.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.4.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.4.1.3. Molecular Diagnostics

14.6.4.1.4. Early Stage Cancer

14.6.4.1.4.1. Lung Cancer

14.6.4.1.4.2. Breast Cancer

14.6.4.1.4.3. Colorectal Cancer

14.6.4.1.4.4. Gastric Cancer

14.6.4.1.4.5. Prostate Cancer

14.6.4.1.4.6. Liver Cancer

14.6.4.1.4.7. Bladder Cancer

14.6.4.1.4.8. Ovarian Cancer

14.6.4.1.4.9. Others

14.6.4.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.4.1.6. Others

14.6.4.2. New Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.4.2.1. 5 ml

14.6.4.2.2. 50 ml

14.6.4.2.3. 100 ml

14.6.4.2.4. 250 ml

14.6.4.2.5. Above 250 ml

14.6.4.3. New Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.4.3.1. Instruments

14.6.4.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.4.3.1.2. Target Selector Kits

14.6.4.3.1.3. Cell Free DNA Extraction Kit

14.6.4.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.4.3.1.5. Mutation Quantification Control Plasma

14.6.4.3.1.6. Genomic Profiling Diagnostics kit

14.6.4.3.1.7. Target Selector NGS Panels

14.6.4.3.1.8. PCR Purification Kit

14.6.4.3.1.9. Blood Nucleic Acid Extraction

14.6.4.3.1.10. Viral Nucleic Acid Extraction

14.6.4.3.1.11. Others

14.6.4.3.2. Reagents

14.6.4.3.3. Liquid Biopsy Assays

14.6.4.3.4. Tools

14.6.4.3.5. Services

14.6.4.3.5.1. Custom Services

14.6.4.3.5.2. Support Services

14.6.4.3.6. Others

14.6.4.4. New Zealand Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.4.4.1. Hospitals/Clinics

14.6.4.4.2. Pathology Laboratories

14.6.4.4.3. Physician Laboratories

14.6.4.4.4. Academic and Research Centers

14.6.4.4.5. Others

14.6.5. Australia

14.6.5.1. Australia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.5.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.5.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.5.1.3. Molecular Diagnostics

14.6.5.1.4. Early Stage Cancer

14.6.5.1.4.1. Lung Cancer

14.6.5.1.4.2. Breast Cancer

14.6.5.1.4.3. Colorectal Cancer

14.6.5.1.4.4. Gastric Cancer

14.6.5.1.4.5. Prostate Cancer

14.6.5.1.4.6. Liver Cancer

14.6.5.1.4.7. Bladder Cancer

14.6.5.1.4.8. Ovarian Cancer

14.6.5.1.4.9. Others

14.6.5.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.5.1.6. Others

14.6.5.2. Australia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.5.2.1. 5 ml

14.6.5.2.2. 50 ml

14.6.5.2.3. 100 ml

14.6.5.2.4. 250 ml

14.6.5.2.5. Above 250 ml

14.6.5.3. Australia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.5.3.1. Instruments

14.6.5.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.5.3.1.2. Target Selector Kits

14.6.5.3.1.3. Cell Free DNA Extraction Kit

14.6.5.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.5.3.1.5. Mutation Quantification Control Plasma

14.6.5.3.1.6. Genomic Profiling Diagnostics kit

14.6.5.3.1.7. Target Selector NGS Panels

14.6.5.3.1.8. PCR Purification Kit

14.6.5.3.1.9. Blood Nucleic Acid Extraction

14.6.5.3.1.10. Viral Nucleic Acid Extraction

14.6.5.3.1.11. Others

14.6.5.3.2. Reagents

14.6.5.3.3. Liquid Biopsy Assays

14.6.5.3.4. Tools

14.6.5.3.5. Services

14.6.5.3.5.1. Custom Services

14.6.5.3.5.2. Support Services

14.6.5.3.6. Others

14.6.5.4. Australia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.5.4.1. Hospitals/Clinics

14.6.5.4.2. Pathology Laboratories

14.6.5.4.3. Physician Laboratories

14.6.5.4.4. Academic and Research Centers

14.6.5.4.5. Others

14.6.6. South Korea

14.6.6.1. South Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.6.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.6.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.6.1.3. Molecular Diagnostics

14.6.6.1.4. Early Stage Cancer

14.6.6.1.4.1. Lung Cancer

14.6.6.1.4.2. Breast Cancer

14.6.6.1.4.3. Colorectal Cancer

14.6.6.1.4.4. Gastric Cancer

14.6.6.1.4.5. Prostate Cancer

14.6.6.1.4.6. Liver Cancer

14.6.6.1.4.7. Bladder Cancer

14.6.6.1.4.8. Ovarian Cancer

14.6.6.1.4.9. Others

14.6.6.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.6.1.6. Others

14.6.6.2. South Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.6.2.1. 5 ml

14.6.6.2.2. 50 ml

14.6.6.2.3. 100 ml

14.6.6.2.4. 250 ml

14.6.6.2.5. Above 250 ml

14.6.6.3. South Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.6.3.1. Instruments

14.6.6.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.6.3.1.2. Target Selector Kits

14.6.6.3.1.3. Cell Free DNA Extraction Kit

14.6.6.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.6.3.1.5. Mutation Quantification Control Plasma

14.6.6.3.1.6. Genomic Profiling Diagnostics kit

14.6.6.3.1.7. Target Selector NGS Panels

14.6.6.3.1.8. PCR Purification Kit

14.6.6.3.1.9. Blood Nucleic Acid Extraction

14.6.6.3.1.10. Viral Nucleic Acid Extraction

14.6.6.3.1.11. Others

14.6.6.3.2. Reagents

14.6.6.3.3. Liquid Biopsy Assays

14.6.6.3.4. Tools

14.6.6.3.5. Services

14.6.6.3.5.1. Custom Services

14.6.6.3.5.2. Support Services

14.6.6.3.6. Others

14.6.6.4. South Korea Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.6.4.1. Hospitals/Clinics

14.6.6.4.2. Pathology Laboratories

14.6.6.4.3. Physician Laboratories

14.6.6.4.4. Academic and Research Centers

14.6.6.4.5. Others

14.6.7. Southeast Asia

14.6.7.1. Southeast Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.7.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.7.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.7.1.3. Molecular Diagnostics

14.6.7.1.4. Early Stage Cancer

14.6.7.1.4.1. Lung Cancer

14.6.7.1.4.2. Breast Cancer

14.6.7.1.4.3. Colorectal Cancer

14.6.7.1.4.4. Gastric Cancer

14.6.7.1.4.5. Prostate Cancer

14.6.7.1.4.6. Liver Cancer

14.6.7.1.4.7. Bladder Cancer

14.6.7.1.4.8. Ovarian Cancer

14.6.7.1.4.9. Others

14.6.7.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.7.1.6. Others

14.6.7.2. Southeast Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.7.2.1. 5 ml

14.6.7.2.2. 50 ml

14.6.7.2.3. 100 ml

14.6.7.2.4. 250 ml

14.6.7.2.5. Above 250 ml

14.6.7.3. Southeast Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.7.3.1. Instruments

14.6.7.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.7.3.1.2. Target Selector Kits

14.6.7.3.1.3. Cell Free DNA Extraction Kit

14.6.7.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.7.3.1.5. Mutation Quantification Control Plasma

14.6.7.3.1.6. Genomic Profiling Diagnostics kit

14.6.7.3.1.7. Target Selector NGS Panels

14.6.7.3.1.8. PCR Purification Kit

14.6.7.3.1.9. Blood Nucleic Acid Extraction

14.6.7.3.1.10. Viral Nucleic Acid Extraction

14.6.7.3.1.11. Others

14.6.7.3.2. Reagents

14.6.7.3.3. Liquid Biopsy Assays

14.6.7.3.4. Tools

14.6.7.3.5. Services

14.6.7.3.5.1. Custom Services

14.6.7.3.5.2. Support Services

14.6.7.3.6. Others

14.6.7.4. Southeast Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.7.4.1. Hospitals/Clinics

14.6.7.4.2. Pathology Laboratories

14.6.7.4.3. Physician Laboratories

14.6.7.4.4. Academic and Research Centers

14.6.7.4.5. Others

14.6.7.5. Southeast Asia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

14.6.7.5.1. Indonesia

14.6.7.5.2. Thailand

14.6.7.5.3. Malaysia

14.6.7.5.4. Singapore

14.6.7.5.5. Rest of Southeast Asia

14.6.8. Rest of Asia Pacific

14.6.8.1. Rest of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

14.6.8.1.1. Circulating Tumor Cells (CTC) in the Blood

14.6.8.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

14.6.8.1.3. Molecular Diagnostics

14.6.8.1.4. Early Stage Cancer

14.6.8.1.4.1. Lung Cancer

14.6.8.1.4.2. Breast Cancer

14.6.8.1.4.3. Colorectal Cancer

14.6.8.1.4.4. Gastric Cancer

14.6.8.1.4.5. Prostate Cancer

14.6.8.1.4.6. Liver Cancer

14.6.8.1.4.7. Bladder Cancer

14.6.8.1.4.8. Ovarian Cancer

14.6.8.1.4.9. Others

14.6.8.1.5. Non-invasive Prenatal Tests (NIPT)

14.6.8.1.6. Others

14.6.8.2. Rest of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

14.6.8.2.1. 5 ml

14.6.8.2.2. 50 ml

14.6.8.2.3. 100 ml

14.6.8.2.4. 250 ml

14.6.8.2.5. Above 250 ml

14.6.8.3. Rest of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

14.6.8.3.1. Instruments

14.6.8.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

14.6.8.3.1.2. Target Selector Kits

14.6.8.3.1.3. Cell Free DNA Extraction Kit

14.6.8.3.1.4. Cell Free Nucleic Acid Extraction Kit

14.6.8.3.1.5. Mutation Quantification Control Plasma

14.6.8.3.1.6. Genomic Profiling Diagnostics kit

14.6.8.3.1.7. Target Selector NGS Panels

14.6.8.3.1.8. PCR Purification Kit

14.6.8.3.1.9. Blood Nucleic Acid Extraction

14.6.8.3.1.10. Viral Nucleic Acid Extraction

14.6.8.3.1.11. Others

14.6.8.3.2. Reagents

14.6.8.3.3. Liquid Biopsy Assays

14.6.8.3.4. Tools

14.6.8.3.5. Services

14.6.8.3.5.1. Custom Services

14.6.8.3.5.2. Support Services

14.6.8.3.6. Others

14.6.8.4. Rest of Asia Pacific Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

14.6.8.4.1. Hospitals/Clinics

14.6.8.4.2. Pathology Laboratories

14.6.8.4.3. Physician Laboratories

14.6.8.4.4. Academic and Research Centers

14.6.8.4.5. Others

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Application

14.7.3. By Size

14.7.4. By Offering

14.7.5. By End User

15. Middle East and Africa Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

15.1. Overview

15.1.1. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn)

15.2. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.2.1. Circulating Tumor Cells (CTC) in the Blood

15.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.2.3. Molecular Diagnostics

15.2.4. Early Stage Cancer

15.2.4.1. Lung Cancer

15.2.4.2. Breast Cancer

15.2.4.3. Colorectal Cancer

15.2.4.4. Gastric Cancer

15.2.4.5. Prostate Cancer

15.2.4.6. Liver Cancer

15.2.4.7. Bladder Cancer

15.2.4.8. Ovarian Cancer

15.2.4.9. Others

15.2.5. Non-invasive Prenatal Tests (NIPT)

15.2.6. Others

15.3. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.3.1. 5 ml

15.3.2. 50 ml

15.3.3. 100 ml

15.3.4. 250 ml

15.3.5. Above 250 ml

15.4. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.4.1. Instruments

15.4.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.4.1.2. Target Selector Kits

15.4.1.3. Cell Free DNA Extraction Kit

15.4.1.4. Cell Free Nucleic Acid Extraction Kit

15.4.1.5. Mutation Quantification Control Plasma

15.4.1.6. Genomic Profiling Diagnostics kit

15.4.1.7. Target Selector NGS Panels

15.4.1.8. PCR Purification Kit

15.4.1.9. Blood Nucleic Acid Extraction

15.4.1.10. Viral Nucleic Acid Extraction

15.4.1.11. Others

15.4.2. Reagents

15.4.3. Liquid Biopsy Assays

15.4.4. Tools

15.4.5. Services

15.4.5.1. Custom Services

15.4.5.2. Support Services

15.4.6. Others

15.5. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.5.1. Hospitals/Clinics

15.5.2. Pathology Laboratories

15.5.3. Physician Laboratories

15.5.4. Academic and Research Centers

15.5.5. Others

15.6. Middle East and Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

15.6.1. Saudi Arabia

15.6.1.1. Saudi Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.1.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.1.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.1.1.3. Molecular Diagnostics

15.6.1.1.4. Early Stage Cancer

15.6.1.1.4.1. Lung Cancer

15.6.1.1.4.2. Breast Cancer

15.6.1.1.4.3. Colorectal Cancer

15.6.1.1.4.4. Gastric Cancer

15.6.1.1.4.5. Prostate Cancer

15.6.1.1.4.6. Liver Cancer

15.6.1.1.4.7. Bladder Cancer

15.6.1.1.4.8. Ovarian Cancer

15.6.1.1.4.9. Others

15.6.1.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.1.1.6. Others

15.6.1.2. Saudi Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.1.2.1. 5 ml

15.6.1.2.2. 50 ml

15.6.1.2.3. 100 ml

15.6.1.2.4. 250 ml

15.6.1.2.5. Above 250 ml

15.6.1.3. Saudi Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.1.3.1. Instruments

15.6.1.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.1.3.1.2. Target Selector Kits

15.6.1.3.1.3. Cell Free DNA Extraction Kit

15.6.1.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.1.3.1.5. Mutation Quantification Control Plasma

15.6.1.3.1.6. Genomic Profiling Diagnostics kit

15.6.1.3.1.7. Target Selector NGS Panels

15.6.1.3.1.8. PCR Purification Kit

15.6.1.3.1.9. Blood Nucleic Acid Extraction

15.6.1.3.1.10. Viral Nucleic Acid Extraction

15.6.1.3.1.11. Others

15.6.1.3.2. Reagents

15.6.1.3.3. Liquid Biopsy Assays

15.6.1.3.4. Tools

15.6.1.3.5. Services

15.6.1.3.5.1. Custom Services

15.6.1.3.5.2. Support Services

15.6.1.3.6. Others

15.6.1.4. Saudi Arabia Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.1.4.1. Hospitals/Clinics

15.6.1.4.2. Pathology Laboratories

15.6.1.4.3. Physician Laboratories

15.6.1.4.4. Academic and Research Centers

15.6.1.4.5. Others

15.6.2. UAE

15.6.2.1. UAE Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.2.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.2.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.2.1.3. Molecular Diagnostics

15.6.2.1.4. Early Stage Cancer

15.6.2.1.4.1. Lung Cancer

15.6.2.1.4.2. Breast Cancer

15.6.2.1.4.3. Colorectal Cancer

15.6.2.1.4.4. Gastric Cancer

15.6.2.1.4.5. Prostate Cancer

15.6.2.1.4.6. Liver Cancer

15.6.2.1.4.7. Bladder Cancer

15.6.2.1.4.8. Ovarian Cancer

15.6.2.1.4.9. Others

15.6.2.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.2.1.6. Others

15.6.2.2. UAE Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.2.2.1. 5 ml

15.6.2.2.2. 50 ml

15.6.2.2.3. 100 ml

15.6.2.2.4. 250 ml

15.6.2.2.5. Above 250 ml

15.6.2.3. UAE Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.2.3.1. Instruments

15.6.2.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.2.3.1.2. Target Selector Kits

15.6.2.3.1.3. Cell Free DNA Extraction Kit

15.6.2.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.2.3.1.5. Mutation Quantification Control Plasma

15.6.2.3.1.6. Genomic Profiling Diagnostics kit

15.6.2.3.1.7. Target Selector NGS Panels

15.6.2.3.1.8. PCR Purification Kit

15.6.2.3.1.9. Blood Nucleic Acid Extraction

15.6.2.3.1.10. Viral Nucleic Acid Extraction

15.6.2.3.1.11. Others

15.6.2.3.2. Reagents

15.6.2.3.3. Liquid Biopsy Assays

15.6.2.3.4. Tools

15.6.2.3.5. Services

15.6.2.3.5.1. Custom Services

15.6.2.3.5.2. Support Services

15.6.2.3.6. Others

15.6.2.4. UAE Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.2.4.1. Hospitals/Clinics

15.6.2.4.2. Pathology Laboratories

15.6.2.4.3. Physician Laboratories

15.6.2.4.4. Academic and Research Centers

15.6.2.4.5. Others

15.6.3. Egypt

15.6.3.1. Egypt Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.3.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.3.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.3.1.3. Molecular Diagnostics

15.6.3.1.4. Early Stage Cancer

15.6.3.1.4.1. Lung Cancer

15.6.3.1.4.2. Breast Cancer

15.6.3.1.4.3. Colorectal Cancer

15.6.3.1.4.4. Gastric Cancer

15.6.3.1.4.5. Prostate Cancer

15.6.3.1.4.6. Liver Cancer

15.6.3.1.4.7. Bladder Cancer

15.6.3.1.4.8. Ovarian Cancer

15.6.3.1.4.9. Others

15.6.3.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.3.1.6. Others

15.6.3.2. Egypt Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.3.2.1. 5 ml

15.6.3.2.2. 50 ml

15.6.3.2.3. 100 ml

15.6.3.2.4. 250 ml

15.6.3.2.5. Above 250 ml

15.6.3.3. Egypt Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.3.3.1. Instruments

15.6.3.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.3.3.1.2. Target Selector Kits

15.6.3.3.1.3. Cell Free DNA Extraction Kit

15.6.3.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.3.3.1.5. Mutation Quantification Control Plasma

15.6.3.3.1.6. Genomic Profiling Diagnostics kit

15.6.3.3.1.7. Target Selector NGS Panels

15.6.3.3.1.8. PCR Purification Kit

15.6.3.3.1.9. Blood Nucleic Acid Extraction

15.6.3.3.1.10. Viral Nucleic Acid Extraction

15.6.3.3.1.11. Others

15.6.3.3.2. Reagents

15.6.3.3.3. Liquid Biopsy Assays

15.6.3.3.4. Tools

15.6.3.3.5. Services

15.6.3.3.5.1. Custom Services

15.6.3.3.5.2. Support Services

15.6.3.3.6. Others

15.6.3.4. Egypt Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.3.4.1. Hospitals/Clinics

15.6.3.4.2. Pathology Laboratories

15.6.3.4.3. Physician Laboratories

15.6.3.4.4. Academic and Research Centers

15.6.3.4.5. Others

15.6.4. Kuwait

15.6.4.1. Kuwait Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.4.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.4.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.4.1.3. Molecular Diagnostics

15.6.4.1.4. Early Stage Cancer

15.6.4.1.4.1. Lung Cancer

15.6.4.1.4.2. Breast Cancer

15.6.4.1.4.3. Colorectal Cancer

15.6.4.1.4.4. Gastric Cancer

15.6.4.1.4.5. Prostate Cancer

15.6.4.1.4.6. Liver Cancer

15.6.4.1.4.7. Bladder Cancer

15.6.4.1.4.8. Ovarian Cancer

15.6.4.1.4.9. Others

15.6.4.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.4.1.6. Others

15.6.4.2. Kuwait Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.4.2.1. 5 ml

15.6.4.2.2. 50 ml

15.6.4.2.3. 100 ml

15.6.4.2.4. 250 ml

15.6.4.2.5. Above 250 ml

15.6.4.3. Kuwait Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.4.3.1. Instruments

15.6.4.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.4.3.1.2. Target Selector Kits

15.6.4.3.1.3. Cell Free DNA Extraction Kit

15.6.4.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.4.3.1.5. Mutation Quantification Control Plasma

15.6.4.3.1.6. Genomic Profiling Diagnostics kit

15.6.4.3.1.7. Target Selector NGS Panels

15.6.4.3.1.8. PCR Purification Kit

15.6.4.3.1.9. Blood Nucleic Acid Extraction

15.6.4.3.1.10. Viral Nucleic Acid Extraction

15.6.4.3.1.11. Others

15.6.4.3.2. Reagents

15.6.4.3.3. Liquid Biopsy Assays

15.6.4.3.4. Tools

15.6.4.3.5. Services

15.6.4.3.5.1. Custom Services

15.6.4.3.5.2. Support Services

15.6.4.3.6. Others

15.6.4.4. Kuwait Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.4.4.1. Hospitals/Clinics

15.6.4.4.2. Pathology Laboratories

15.6.4.4.3. Physician Laboratories

15.6.4.4.4. Academic and Research Centers

15.6.4.4.5. Others

15.6.5. South Africa

15.6.5.1. South Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.5.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.5.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.5.1.3. Molecular Diagnostics

15.6.5.1.4. Early Stage Cancer

15.6.5.1.4.1. Lung Cancer

15.6.5.1.4.2. Breast Cancer

15.6.5.1.4.3. Colorectal Cancer

15.6.5.1.4.4. Gastric Cancer

15.6.5.1.4.5. Prostate Cancer

15.6.5.1.4.6. Liver Cancer

15.6.5.1.4.7. Bladder Cancer

15.6.5.1.4.8. Ovarian Cancer

15.6.5.1.4.9. Others

15.6.5.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.5.1.6. Others

15.6.5.2. South Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.5.2.1. 5 ml

15.6.5.2.2. 50 ml

15.6.5.2.3. 100 ml

15.6.5.2.4. 250 ml

15.6.5.2.5. Above 250 ml

15.6.5.3. South Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.5.3.1. Instruments

15.6.5.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.5.3.1.2. Target Selector Kits

15.6.5.3.1.3. Cell Free DNA Extraction Kit

15.6.5.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.5.3.1.5. Mutation Quantification Control Plasma

15.6.5.3.1.6. Genomic Profiling Diagnostics kit

15.6.5.3.1.7. Target Selector NGS Panels

15.6.5.3.1.8. PCR Purification Kit

15.6.5.3.1.9. Blood Nucleic Acid Extraction

15.6.5.3.1.10. Viral Nucleic Acid Extraction

15.6.5.3.1.11. Others

15.6.5.3.2. Reagents

15.6.5.3.3. Liquid Biopsy Assays

15.6.5.3.4. Tools

15.6.5.3.5. Services

15.6.5.3.5.1. Custom Services

15.6.5.3.5.2. Support Services

15.6.5.3.6. Others

15.6.5.4. South Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.5.4.1. Hospitals/Clinics

15.6.5.4.2. Pathology Laboratories

15.6.5.4.3. Physician Laboratories

15.6.5.4.4. Academic and Research Centers

15.6.5.4.5. Others

15.6.6. Rest of Middle East & Africa

15.6.6.1. Rest of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

15.6.6.1.1. Circulating Tumor Cells (CTC) in the Blood

15.6.6.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

15.6.6.1.3. Molecular Diagnostics

15.6.6.1.4. Early Stage Cancer

15.6.6.1.4.1. Lung Cancer

15.6.6.1.4.2. Breast Cancer

15.6.6.1.4.3. Colorectal Cancer

15.6.6.1.4.4. Gastric Cancer

15.6.6.1.4.5. Prostate Cancer

15.6.6.1.4.6. Liver Cancer

15.6.6.1.4.7. Bladder Cancer

15.6.6.1.4.8. Ovarian Cancer

15.6.6.1.4.9. Others

15.6.6.1.5. Non-invasive Prenatal Tests (NIPT)

15.6.6.1.6. Others

15.6.6.2. Rest of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

15.6.6.2.1. 5 ml

15.6.6.2.2. 50 ml

15.6.6.2.3. 100 ml

15.6.6.2.4. 250 ml

15.6.6.2.5. Above 250 ml

15.6.6.3. Rest of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

15.6.6.3.1. Instruments

15.6.6.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

15.6.6.3.1.2. Target Selector Kits

15.6.6.3.1.3. Cell Free DNA Extraction Kit

15.6.6.3.1.4. Cell Free Nucleic Acid Extraction Kit

15.6.6.3.1.5. Mutation Quantification Control Plasma

15.6.6.3.1.6. Genomic Profiling Diagnostics kit

15.6.6.3.1.7. Target Selector NGS Panels

15.6.6.3.1.8. PCR Purification Kit

15.6.6.3.1.9. Blood Nucleic Acid Extraction

15.6.6.3.1.10. Viral Nucleic Acid Extraction

15.6.6.3.1.11. Others

15.6.6.3.2. Reagents

15.6.6.3.3. Liquid Biopsy Assays

15.6.6.3.4. Tools

15.6.6.3.5. Services

15.6.6.3.5.1. Custom Services

15.6.6.3.5.2. Support Services

15.6.6.3.6. Others

15.6.6.4. Rest of Middle East & Africa Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

15.6.6.4.1. Hospitals/Clinics

15.6.6.4.2. Pathology Laboratories

15.6.6.4.3. Physician Laboratories

15.6.6.4.4. Academic and Research Centers

15.6.6.4.5. Others

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Application

15.7.3. By Size

15.7.4. By Offering

15.7.5. By End User

16. Latin America Liquid Biopsy Products Market Analysis and Forecasts, 2022 – 2030

16.1. Overview

16.1.1. Latin America Liquid Biopsy Products Market Revenue (US$ Mn)

16.2. Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

16.2.1. Circulating Tumor Cells (CTC) in the Blood

16.2.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

16.2.3. Molecular Diagnostics

16.2.4. Early Stage Cancer

16.2.4.1. Lung Cancer

16.2.4.2. Breast Cancer

16.2.4.3. Colorectal Cancer

16.2.4.4. Gastric Cancer

16.2.4.5. Prostate Cancer

16.2.4.6. Liver Cancer

16.2.4.7. Bladder Cancer

16.2.4.8. Ovarian Cancer

16.2.4.9. Others

16.2.5. Non-invasive Prenatal Tests (NIPT)

16.2.6. Others

16.3. Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

16.3.1. 5 ml

16.3.2. 50 ml

16.3.3. 100 ml

16.3.4. 250 ml

16.3.5. Above 250 ml

16.4. Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

16.4.1. Instruments

16.4.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

16.4.1.2. Target Selector Kits

16.4.1.3. Cell Free DNA Extraction Kit

16.4.1.4. Cell Free Nucleic Acid Extraction Kit

16.4.1.5. Mutation Quantification Control Plasma

16.4.1.6. Genomic Profiling Diagnostics kit

16.4.1.7. Target Selector NGS Panels

16.4.1.8. PCR Purification Kit

16.4.1.9. Blood Nucleic Acid Extraction

16.4.1.10. Viral Nucleic Acid Extraction

16.4.1.11. Others

16.4.2. Reagents

16.4.3. Liquid Biopsy Assays

16.4.4. Tools

16.4.5. Services

16.4.5.1. Custom Services

16.4.5.2. Support Services

16.4.6. Others

16.5. Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

16.5.1. Hospitals/Clinics

16.5.2. Pathology Laboratories

16.5.3. Physician Laboratories

16.5.4. Academic and Research Centers

16.5.5. Others

16.6. Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1. Brazil Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

16.6.1.1.1. Circulating Tumor Cells (CTC) in the Blood

16.6.1.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

16.6.1.1.3. Molecular Diagnostics

16.6.1.1.4. Early Stage Cancer

16.6.1.1.4.1. Lung Cancer

16.6.1.1.4.2. Breast Cancer

16.6.1.1.4.3. Colorectal Cancer

16.6.1.1.4.4. Gastric Cancer

16.6.1.1.4.5. Prostate Cancer

16.6.1.1.4.6. Liver Cancer

16.6.1.1.4.7. Bladder Cancer

16.6.1.1.4.8. Ovarian Cancer

16.6.1.1.4.9. Others

16.6.1.1.5. Non-invasive Prenatal Tests (NIPT)

16.6.1.1.6. Others

16.6.1.2. Brazil Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

16.6.1.2.1. 5 ml

16.6.1.2.2. 50 ml

16.6.1.2.3. 100 ml

16.6.1.2.4. 250 ml

16.6.1.2.5. Above 250 ml

16.6.1.3. Brazil Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

16.6.1.3.1. Instruments

16.6.1.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

16.6.1.3.1.2. Target Selector Kits

16.6.1.3.1.3. Cell Free DNA Extraction Kit

16.6.1.3.1.4. Cell Free Nucleic Acid Extraction Kit

16.6.1.3.1.5. Mutation Quantification Control Plasma

16.6.1.3.1.6. Genomic Profiling Diagnostics kit

16.6.1.3.1.7. Target Selector NGS Panels

16.6.1.3.1.8. PCR Purification Kit

16.6.1.3.1.9. Blood Nucleic Acid Extraction

16.6.1.3.1.10. Viral Nucleic Acid Extraction

16.6.1.3.1.11. Others

16.6.1.3.2. Reagents

16.6.1.3.3. Liquid Biopsy Assays

16.6.1.3.4. Tools

16.6.1.3.5. Services

16.6.1.3.5.1. Custom Services

16.6.1.3.5.2. Support Services

16.6.1.3.6. Others

16.6.1.4. Brazil Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

16.6.1.4.1. Hospitals/Clinics

16.6.1.4.2. Pathology Laboratories

16.6.1.4.3. Physician Laboratories

16.6.1.4.4. Academic and Research Centers

16.6.1.4.5. Others

16.6.2. Argentina

16.6.2.1. Argentina Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

16.6.2.1.1. Circulating Tumor Cells (CTC) in the Blood

16.6.2.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

16.6.2.1.3. Molecular Diagnostics

16.6.2.1.4. Early Stage Cancer

16.6.2.1.4.1. Lung Cancer

16.6.2.1.4.2. Breast Cancer

16.6.2.1.4.3. Colorectal Cancer

16.6.2.1.4.4. Gastric Cancer

16.6.2.1.4.5. Prostate Cancer

16.6.2.1.4.6. Liver Cancer

16.6.2.1.4.7. Bladder Cancer

16.6.2.1.4.8. Ovarian Cancer

16.6.2.1.4.9. Others

16.6.2.1.5. Non-invasive Prenatal Tests (NIPT)

16.6.2.1.6. Others

16.6.2.2. Argentina Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

16.6.2.2.1. 5 ml

16.6.2.2.2. 50 ml

16.6.2.2.3. 100 ml

16.6.2.2.4. 250 ml

16.6.2.2.5. Above 250 ml

16.6.2.3. Argentina Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

16.6.2.3.1. Instruments

16.6.2.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

16.6.2.3.1.2. Target Selector Kits

16.6.2.3.1.3. Cell Free DNA Extraction Kit

16.6.2.3.1.4. Cell Free Nucleic Acid Extraction Kit

16.6.2.3.1.5. Mutation Quantification Control Plasma

16.6.2.3.1.6. Genomic Profiling Diagnostics kit

16.6.2.3.1.7. Target Selector NGS Panels

16.6.2.3.1.8. PCR Purification Kit

16.6.2.3.1.9. Blood Nucleic Acid Extraction

16.6.2.3.1.10. Viral Nucleic Acid Extraction

16.6.2.3.1.11. Others

16.6.2.3.2. Reagents

16.6.2.3.3. Liquid Biopsy Assays

16.6.2.3.4. Tools

16.6.2.3.5. Services

16.6.2.3.5.1. Custom Services

16.6.2.3.5.2. Support Services

16.6.2.3.6. Others

16.6.2.4. Argentina Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

16.6.2.4.1. Hospitals/Clinics

16.6.2.4.2. Pathology Laboratories

16.6.2.4.3. Physician Laboratories

16.6.2.4.4. Academic and Research Centers

16.6.2.4.5. Others

16.6.3. Rest of Latin America

16.6.3.1. Rest of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Application

16.6.3.1.1. Circulating Tumor Cells (CTC) in the Blood

16.6.3.1.2. Cell Free DNA from Tumor or Fetus Cells (in the blood)

16.6.3.1.3. Molecular Diagnostics

16.6.3.1.4. Early Stage Cancer

16.6.3.1.4.1. Lung Cancer

16.6.3.1.4.2. Breast Cancer

16.6.3.1.4.3. Colorectal Cancer

16.6.3.1.4.4. Gastric Cancer

16.6.3.1.4.5. Prostate Cancer

16.6.3.1.4.6. Liver Cancer

16.6.3.1.4.7. Bladder Cancer

16.6.3.1.4.8. Ovarian Cancer

16.6.3.1.4.9. Others

16.6.3.1.5. Non-invasive Prenatal Tests (NIPT)

16.6.3.1.6. Others

16.6.3.2. Rest of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Size

16.6.3.2.1. 5 ml

16.6.3.2.2. 50 ml

16.6.3.2.3. 100 ml

16.6.3.2.4. 250 ml

16.6.3.2.5. Above 250 ml

16.6.3.3. Rest of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By Offering

16.6.3.3.1. Instruments

16.6.3.3.1.1. Blood Collection Tube (BCT) for cfDNA and CTCs

16.6.3.3.1.2. Target Selector Kits

16.6.3.3.1.3. Cell Free DNA Extraction Kit

16.6.3.3.1.4. Cell Free Nucleic Acid Extraction Kit

16.6.3.3.1.5. Mutation Quantification Control Plasma

16.6.3.3.1.6. Genomic Profiling Diagnostics kit

16.6.3.3.1.7. Target Selector NGS Panels

16.6.3.3.1.8. PCR Purification Kit

16.6.3.3.1.9. Blood Nucleic Acid Extraction

16.6.3.3.1.10. Viral Nucleic Acid Extraction

16.6.3.3.1.11. Others

16.6.3.3.2. Reagents

16.6.3.3.3. Liquid Biopsy Assays

16.6.3.3.4. Tools

16.6.3.3.5. Services

16.6.3.3.5.1. Custom Services

16.6.3.3.5.2. Support Services

16.6.3.3.6. Others

16.6.3.4. Rest of Latin America Liquid Biopsy Products Market Revenue (US$ Mn) and Forecasts, By End User

16.6.3.4.1. Hospitals/Clinics

16.6.3.4.2. Pathology Laboratories

16.6.3.4.3. Physician Laboratories

16.6.3.4.4. Academic and Research Centers

16.6.3.4.5. Others

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Application

16.7.3. By Size

16.7.4. By Offering

16.7.5. By End User

17. Competitive Benchmarking

17.1. Market Share Analysis, 2021

17.2. Global Presence and Growth Strategies

17.2.1. Mergers and Acquisitions

17.2.2. Product Launches

17.2.3. Investments Trends

17.2.4. R&D Initiatives

18. Player Profiles

18.1. Biocept, Inc.

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. BioChain Institute Inc.

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. Bio-Rad Laboratories, Inc.

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. F. Hoffmann-La Roche Ltd

18.4.1. Company Details

18.4.2. Company Overview

18.4.3. Product Offerings

18.4.4. Key Developments

18.4.5. Financial Analysis

18.4.6. SWOT Analysis

18.4.7. Business Strategies

18.5. Genomic Health

18.5.1. Company Details

18.5.2. Company Overview

18.5.3. Product Offerings

18.5.4. Key Developments

18.5.5. Financial Analysis

18.5.6. SWOT Analysis

18.5.7. Business Strategies

18.6. Grail Bio in collaboration an Illumina spinoff

18.6.1. Company Details

18.6.2. Company Overview

18.6.3. Product Offerings

18.6.4. Key Developments

18.6.5. Financial Analysis

18.6.6. SWOT Analysis

18.6.7. Business Strategies

18.7. Guardant Health

18.7.1. Company Details

18.7.2. Company Overview

18.7.3. Product Offerings

18.7.4. Key Developments

18.7.5. Financial Analysis

18.7.6. SWOT Analysis

18.7.7. Business Strategies

18.8. MDxHealth.

18.8.1. Company Details

18.8.2. Company Overview

18.8.3. Product Offerings

18.8.4. Key Developments

18.8.5. Financial Analysis

18.8.6. SWOT Analysis

18.8.7. Business Strategies

18.9. Myriad Genetics

18.9.1. Company Details

18.9.2. Company Overview

18.9.3. Product Offerings

18.9.4. Key Developments

18.9.5. Financial Analysis

18.9.6. SWOT Analysis

18.9.7. Business Strategies

18.10. Pathway Genomics

18.10.1. Company Details

18.10.2. Company Overview

18.10.3. Product Offerings

18.10.4. Key Developments

18.10.5. Financial Analysis

18.10.6. SWOT Analysis

18.10.7. Business Strategies

18.11. Personal Genome Diagnostics Inc.

18.11.1. Company Details

18.11.2. Company Overview

18.11.3. Product Offerings

18.11.4. Key Developments

18.11.5. Financial Analysis

18.11.6. SWOT Analysis

18.11.7. Business Strategies

18.12. QIAGEN

18.12.1. Company Details

18.12.2. Company Overview

18.12.3. Product Offerings

18.12.4. Key Developments

18.12.5. Financial Analysis

18.12.6. SWOT Analysis

18.12.7. Business Strategies

18.13. Other Market Participants

19. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $4600

Multi users $8200

Global users $9100

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com